Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor, exerts remarkable effects against EGFR T790M resistance mutation-positive non-small cell lung cancer. Identifying T790M mutation by re-biopsy is essential before prescribing osimertinib. Tissue bi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Kobayashi, Keigo, Naoki, Katsuhiko, Manabe, Tadashi, Masuzawa, Keita, Hasegawa, Hanako, Yasuda, Hiroyuki, Kawada, Ichiro, Soejima, Kenzo, Betsuyaku, Tomoko
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2018
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995408/
https://ncbi.nlm.nih.gov/pubmed/29922072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S161745
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller